NUCANA

A New Era in Oncology

Corporate Presentation

June 2023

Disclaimer

Forward-Looking Statements

This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the "Company"). All statements other than statements of historical fact contained in this presentation are forward-looking statements. Forward-looking statements include information concerning the company's planned and ongoing preclinical and clinical studies for the Company's product candidates and the potential advantages of those product candidates, including NUC-3373 and NUC-7738; the initiation, enrollment, timing, progress, release of data from and results of the Company's planned and ongoing clinical studies; the impact of COVID-19 on its preclinical studies, clinical studies, business, financial condition and results of operations; the utility of prior preclinical and clinical data in determining future clinical results; the timing or likelihood of regulatory filings and approvals for any of its product candidates; the Company's intellectual property; the amount and sufficiency of the Company's cash and cash equivalents to achieve its projected milestones and to fund its planned operations into 2025; and estimates regarding the Company's expenses, future revenues and future capital requirements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "believes," "estimates," "potential" or "continue" or the negative of these terms or other comparable terminology.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the "Risk Factors" section of our Annual Report on Form 20-F for the year ended December 31, 2022 filed with the Securities and Exchange Commission ("SEC") on April 4, 2023, and subsequent reports that the Company files with the SEC.


Forward-looking statements represent the Company's beliefs and assumptions only as of the date of this presentation. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this presentation to conform any of the forward-looking statements to actual results or to changes in its expectations.

Trademarks

NuCana, the NuCana logo and other trademarks or service marks of NuCana plc appearing in this presentation are the property of NuCana plc. Trade names, trademarks and service marks of other companies appearing in this presentation are the property of their respective owners. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may be without the @ and m symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights to these trademarks, service marks and trade names.




Harnessing the Power of Phosphoramidate Chemistry




A New Era in Oncology



Nucleoside Analogs: Cornerstones of Cancer Treatment



Transforming Nucleoside Analogs into ProTides



ProTides: A New Era In Anti-Virals





Transforms Therapeutic Index

Overcomes Viral Resistance Mechanisms

¹ Sovaldi + Harvoni + Epclusa + Vosevi cumulative sales through 31 March 2023
² Genvoya + Descovy + Odefsey + Biktarvy + Symtuza cumulative sales through 31 March 2023
³ Veklury cumulative sales through 31 March 2023

ProTides: A New Era in Oncology

NUCANA



Transforms Therapeutic Index

Overcomes Cancer Resistance Mechanisms

¹ Pre-clinical data - Ghazaly *et al* ESMO September 2017 ² Pre-clinical data – Symeonides *et al* ESMO September 2020


INDICATION	COMBINATION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Coloroctal Capcor	irinotecan bevacizumab				
	oxaliplatin bevacizumab				
Colorectal Cancer second-line	irinotecan bevacizumab				
Solid Tumors	pembrolizumab				
Lung Cancer	docetaxel				
	Colorectal Cancer	Colorectal Cancer irinotecan bevacizumab Oxaliplatin bevacizumab Colorectal Cancer second-line Dirinotecan bevacizumab Solid Tumors Pembrolizumab	Image: Market intervalue	Colorectal Cancer Second-lineirinotecan bevacizumabiOxaliplatin bevacizumabIIOxaliplatin bevacizumabIIImage: Second-lineImage: Second-lineImage: Second-lineSolid TumorspembrolizumabImage: Second-lineImage: Second-line	Image: Colorectal Cancer irinotecan bevacizumab Image: Colorectal Cancer bevacizumab Image: Colorectal Cancer

NUC-7738				
No. 701 a. 1	Solid Tumors			
NUTIDE 701 Study	Solid Tumors	pembrolizumab		



Strong Balance Sheet & Multiple Inflection Points









A transformation of 5-FU

NUC-3373: Overview of Fluorouracil (5-FU)



- WHO List of Essential Medicines
- ~500,000 patients receive 5-FU annually in North America
- SOC for 16 of the 25 most common cancers
- 10-15% Overall Response Rate (first-line colorectal cancer)



Limitations of Fluorouracil (5-FU)



Breakdown & Toxicity >85% breakdown by DPD Toxic metabolites: FBAL & FUTP



active transport




Inefficient generation of anti-cancer metabolite




46-hour continuous infusion



NUC-3373: 5-FU Metabolism Comparison & Mechanism of Action




NUC-3373 is a potent TS inhibitor and does not generate the toxic metabolite FUTP



Bre *et al* (2022) Abstract ID 1835 (AACR April 2022) Non-clinical data presented as AUC in HCT116 human colorectal cancer cells treated with NUC-3373 or 5-FU

NUC-3373: Greater Anti-Cancer Activity than 5-FU




NUC-3373 had up to 330x greater anti-cancer activity than 5-FU

Ghazaly et al (2017) Ann Oncol; 25: Suppl 5 Abstract ID:385P (ESMO September 2017)



NUC-3373: Solid Tumor Phase 1 Study







Spiliopoulou et al (2021) Ann Oncol; 32: Suppl 5 Abstract ID 549P (ESMO September 2021)

Favorable Safety Profile

Treatment Related Adverse Events* (n=59)							
	Grade 1 & 2 n (%)	Grade 3 n (%)	Grade 4 n (%)				
Fatigue	26 (44%)	1 (2%)	0				
Nausea	21 (36%)	0	0				
Diarrhea	18 (31%)	0	0				
Infusion reaction	17 (29%)	0	0				
Transaminases increased	7 (12%)	4 (7%)	0				
Anemia	9 (15%)	0	0				
Vomiting	9 (15%)	0	0				
Constipation	7 (12%)	0	0				

NUCANA

MTD for NUC-3373 monotherapy was 2,500 mg/m² Q1W



NUC-3373: Solid Tumor Phase 1 Study

Metastatic Colorectal Cancer

70 years, male 6 prior lines

 5-FU: based chemoradiotherapy (adjuvant)
FOLFIRI: for metastatic disease
CAPOX: progressed within 2 months
FOLFIRI: progressed within 8 months
LONSURF: progressed within 3 months
Irinotecan: treatment for 1 month

> NUC-3373 1,500 mg/m² Q1W

Stable Disease: 9 months

Metastatic Basal Cell Carcinoma

55 years, male **2 prior lines**

 Vismodegib: for **11 months** Paclitaxel + carboplatin: for **3 months** Metastatic Cholangiocarcinoma

60 years, female **1 prior line**

1) Gemcitabine + cisplatin: progressed within **6 months**


NUC-3373 1,500 mg/m² Q2W

Stable Disease: 10 months NUC-3373 1,125 mg/m² Q1W

Stable Disease: **11 months**


NUTIDE 301

Spiliopoulou *et al* (2021) *Ann Oncol*; 32: Suppl 5 Abstract ID 549P (ESMO September 2021) Data cut-off-off: August 17, 2021 NUC-3373: Colorectal Cancer Market Opportunity



NUC-3373: 5-FU is the Cornerstone of CRC Treatment

						5-FU based	d regimens	Non-5	-FU based r	regimens
				Percent	age of Trea	atable Mark	et			
	10%	20%	30%	40%	50%	60%	70%	80%	90%	100%
Neo/Adjuvant				F	FOLFOX / c	АРОХ				
1 st Line				X / CAPOX eted agent				FOLFIRI / ± target		10
Maintenance				5-FU / 0	capecitabine	± targeted agent				
2 nd Line			FOLF ± targeted					FOLFOX ± targeted agent		Targeted therapies
≥3 rd Line	FOLFIRI / FOL ± targeted agen		5-FU /	capecitabine	2		nsurf (TAS- /arga (regor			al study/)ther




```
NUCANA
```



Patients with advanced colorectal cancer


- Part 1 (NUC-3373 + leucovorin)
 - Received ≥2 prior lines of fluoropyrimidine-based regimens
 - Exhausted all other therapeutic options

NUTIDE 302 part 1



Berlin et al. (2021) Ann Oncol; 32: Suppl 5 Abstract ID 745P (ESMO September 2021). Data cut-off: April 15, 2021

Favorable Pharmacokinetic Profile





Coveler et al (2021) J Clin Oncol 39: Suppl 3 Abstract ID: 93 (ASCO GI January 2021). Data cut off: Nov 26, 2020


Favorable Safety Profile

	NUC-3373 (n=38) ¹		5-FU Bolus (n=219) ²		5-FU CIV (n=143) ²		Capecitabine (n=596) ³	
Category	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%)
Neutropenia	0	0	99	67	48	13	13	3
Anemia	18	5	99	6	91	2	80	3
Diarrhea	32	0	70	13	45	6	55	15
Nausea	45	5	68	8	55	4	43	4
Vomiting	42	0	46	4	32	3	27	5
Mucositis/stomatitis	11	0	76	17	29	3	25	3
Hand-foot syndrome	0	0	NR	NR	13	1	54	17
Dermatitis	11	0	30	1	20	0	27	1
Fatigue/asthenia	47	5	65	12	48	4	42	4
Elevated bilirubin	11	5	92	8	36	11	48	23
	Heavily pre-treated patients NUC-3373 ± LV Q1W or Q2W		First-line patients 5-FU/LV bolus days 1-5, Q4W		First-line patients 5-FU/LV CIV days 1&2, Q2W		First-line patients Capecitabine BID 2wks on/1wk off	

- Grade 4 treatment-related AE (1x bilirubin)
- Grade 3 treatment-related AEs (2x ALT, 2x ALP, 2x nausea, 2x anemia, 1x AST, 1x hyponatremia, 1x fever, 1x fatigue)
- FUTP, the primary cause of 5-FU toxicity and a dose-limiting factor, has not been detected in NUC-3373 treated patients

NUC-3373 All-cause adverse events, selected relevant to comparator data. NR: not reported 1. Berlin *et al.* (2021) *Ann Oncol*; 32: Suppl 5 Abstract ID 745P (ESMO September 2021). Data cut-off: April 15, 2021 2. Camptosar Label 3. XELODA label





NUCANA

Selected case studies in patients who achieved ≥3 months on study

Berlin et al (2021) Ann Oncol; 32: Suppl 5 Abstract ID 745P (ESMO September 2021). Data cut-off: April 15, 2021



Colorectal Cancer

67 years, female **3 prior lines**

1) CAPOX (adjuvant): for **3 months** relapsed 9 months post-adjuvant therapy

2) FOLFIRI: progressed within **3 months**

3) Lonsurf: progressed within **3 months**

> RAS unknown Target lesions: 1 (peritoneum)

NUC-3373 2,500 mg/m² Q1W **40% reduction** in target lesion

> Partial Response: **3.5 months**

Colorectal Cancer

69 years, male **2 prior lines**

Diagnosed with metastatic disease

- 1) CAPOX: progressed within **2 months** tumor **increase of 35%**
- 2) FOLFIRI: progressed within **1.5 months**

RAS unknown Target lesions: 2 (liver)

NUC-3373 1,500 mg/m² Q1W **28% reduction** in tumor volume

Stable Disease: 5.1 months*

* patient missed 6 consecutive doses due to COVID-19 and progressed, but continued on study for a total of 8 months due to clinical benefit

NUCANA

Colorectal Cancer

52 years, male **5 prior lines**

 FOLFOX (adjuvant): for 4 months relapsed 4 months post-adjuvant therapy
FOLFIRI:

progressed within 6 months

- 3) Irinotecan + panitumumab: progressed within **6 months**
- 4) Irinotecan + panitumumab + telaglenastat: progressed within **6 months**
- 5) Nivolumab + enadenotucirev: progressed within **3 months**

RAS wildtype; BRAF mutant Target lesions: 3 (2 lung; 1 liver)

NUC-3373 1,500 mg/m² Q2W

15% reduction in tumor volume

Stable Disease: 4.5 months



Graham *et al* (2020) *Ann Oncol* 31: Suppl 4 Abstract ID :464P (ESMO September 2020). Data cut off: August 14, 2020 Coveler *et al* (2021) *J Clin Oncol* 39: Suppl 3 Abstract ID: 93 (ASCO GI January 2021) . Data cut off: Nov 26, 2020

Colorectal Cancer

47 years, male 4 prior lines

 FOLFOX (adjuvant): for 5 months relapsed 8 months post-adjuvant therapy

2) FOLFIRI + bevacizumab: progressed within **18 months**

3) FOLFIRI + cetuximab: progressed within **8 months**

4) Lonsurf: toxicity within **3 months**

> RAS wildtype Target lesions: 5 (2 lymph nodes; 2 peritoneum; 1 liver)

> > NUC-3373 1,500 mg/m² Q1W

Stable Disease: **5.1 months**

Colorectal Cancer

57 years, male 4 prior lines

 CAPOX (neoadjuvant/adjuvant): for 6 months relapsed 2 months post-adjuvant therapy
FOLFIRI: progressed within 3 months

3) Lonsurf: progressed within **2 months**

4) RXCOO4 (Wnt inhibitor): progressed within **1 month**

> RAS unknown Target lesions: 3 (lung)

NUC-3373 1,500 mg/m² Q1W

Stable Disease: **3.8 months**

Colorectal Cancer

67 years, female **5 prior lines**

1) FOLFOX (adjuvant): for **5 months** relapsed 2 years post-adjuvant therapy

2) FOLFIRI: for **5 months**

3) Irinotecan + Lonsurf + bevacizumab for **33 months**

4) CAPOX: progressed within **1 month**

5) Regorafenib: progressed within 2 months


RAS mutant Target lesions: 2 (1 liver; 1 abdomen)

> NUC-3373 1,500 mg/m² Q1W


Stable Disease: **3.1 months**

NUTIDE 302 part 1

Graham *et al* (2020) *Ann Oncol* 31: Suppl 4 Abstract ID :464P (ESMO September 2020). Data cut off: August 14, 2020 Coveler *et al* (2021) *J Clin Oncol* 39: Suppl 3 Abstract ID: 93 (ASCO GI January 2021). Data cut off: Nov 26, 2020



NUCANA



Coveler et al (2022) Ann Oncol; 33: Suppl 7 Abstract ID 354P (ESMO September 2022). Data cut-off: August 5, 2022

NUCANA

Favorable Safety Profile

	Treatment Related Adverse Events								
	Г	NUFIRI at MT (n=9)	D	NUFOX at MTD (n=10)					
	Grade 1 or 2	Grade 3	Grade 4	Grade 1 or 2	Grade 3	Grade 4			
Nausea	4 (44%)	0	0	4 (40%)	1 (10%)	0			
Diarrhea	1 (11%)	0	0	4 (40%)	0	0			
Vomiting	2 (22%)	0	0	3 (30%)	1 (10%)	0			
Stomatitis	0	0	0	1 (10%)	0	0			
ALT increased	0	2 (22%)	0	1 (10%)	0	0			
AST increased	1 (11%)	0	0	2 (20%)	0	0			
ALP increased	0	1 (11%)	0	0	0	0			
Appetite decreased	2 (22%)	0	0	3 (30%)	0	0			
Hypokalemia	0	0	0	0	1 (10%)	0			
Hypomagnesemia	2 (22%)	0	0	0	0	0			
Anemia	2 (22%)	0	0	1 (10%)	0	0			
Thrombocytopenia	0	0	0	0	1 (10%)	0			
Fatigue	2 (22%)	1 (11%)	0	5 (50%)	0	0			
Infusion-related reaction	0	0	0	2 (20%)	0	0			

Treatment Polated Adverse Events

Treatment related adverse events reported are related to NUC-3373, NUC-3373 & oxaliplatin or NUC-3373 & irinotecan

All grade TRAEs with incidence of \geq 10% in any dose cohort; All grade 3 TRAEs reported

MTD of NUFIRI= NUC-3373 1,500 mg/m² + irinotecan 180 mg/m² ; MTD of NUFOX= NUC-3373 1,875 mg/m² + oxaliplatin 85 mg/m²

NUTIDE 302 part 2


Coveler et al (2022) Ann Oncol; 33: Suppl 7 Abstract ID 354P (ESMO September 2022). Data cut-off: August 5, 2022



Durable Disease Control NUFIRI NUC-3373 / irinotecan dose 1500 / 120 mg/m² 1500 / 150 mg/m² 1500 / 180 mg/m² 1875 / 180 mg/m² -> ongoing 🛆 PD 1 2 3 4 5 6 7 8 Months **NUFOX** NUC-3373 dose 1500 mg/m² 1875 mg/m² 2250 mg/m² -> ongoing 🛆 PD 2 3 5 6 7 1 4 8 Months NUTIDE 302 part 2

Coveler et al (2022) Ann Oncol; 33: Suppl 7 Abstract ID 354P (ESMO September 2022). Data cut-off: August 5, 2022

NUC-3373: Colorectal Randomized Phase 2 Study



Q1W NUFIRI +bevacizumab= 1,500 mg/m² NUC-3373 (Q1W), 400 mg/m² LV (Q1W), 180 mg/m² irinotecan (Q2W) and 5mg/kg bevacizumab (Q2W)


Q2W NUFIRI +bevacizumab= 1,500 mg/m² NUC-3373 (Q2W), 400 mg/m² LV (Q2W), 180 mg/m² irinotecan (Q2W) and 5mg/kg bevacizumab (Q2W)

Q2W FOLFIRI +bevacizumab= 400 mg/m² bolus 5-FU followed by 2,400 mg/m² continuous IV 5-FU (Q2W), 400 mg/m² LV (Q2W), 180 mg/m² irinotecan (Q2W) and 5mg/kg bevacizumab (Q2W)




NUCANA

NUC-3373: Additional Mechanisms of Action



NUCANA


NUC-3373: Additional Indications Phase 1b/2 Study








A transformation of 3'-deoxyadenosine







1950: **3'-dA** isolated from *Cordyceps sinensis*



NUC-7738: RNA Polyadenylation Disruptor





NUCANA



Patients with metastatic cancer who have exhausted all therapeutic options

Phase 1

- Solid Tumors
- Objective: Recommended Phase 2 Dose

Phase 2


- Solid Tumors
- Objective: Efficacy and Safety






NUCANA

Favorable Pharmacokinetic Profile







Symeonides et al (2022) Ann Oncol: 33: Suppl 7 Abstract ID 455MO (ESMO oral September 2022). Data cut off: July 7, 2022

NUCANA

Patients with Treatment-Related Adverse Events (TRAEs)							MTD							
Dose AE occurred (mg/m ²)	14 n*=2	28 n*=3	42 n*=2	70 n*=3	112 n*=4	182 n*=4	273 n*=5	400 n*=6	600 n*=9	750 n*=5	900 n*=8	1,350 n*=11	2,000 n*=2	Total*' n=38
All Grade TRAEs (≥10%)														
Nausea	0	1 (33%)	0	0	0	0	1 (20%)	0	3 (33%)	2 (40%)	3 (38%)	5 (45%)	1 (50%)	16 (42%)
Fatigue	0	1 (33%)	0	0	0	0	0	1 (17%)	3 (33%)	1 (20%)	3 (38%)	7 (64%)	2 (100%)	14 (37%)
Anemia	0	0	0	0	0	0	0	0	0	0	2 (25%)	4 (36%)	2 (100%)	7 (18%)
Diarrhea	0	0	0	0	0	0	1 (20%)	0	0	1 (20%)	1 (13%)	4 (36%)	0	6 (16%)
Vomiting	0	0	0	0	0	0	0	0	0	1 (20%)	1 (13%)	3 (27%)	1 (50%)	6 (16%)
Mucosal inflammation	0	0	0	0	0	0	0	0	1 (11%)	1 (20%)	0	1 (9%)	1 (50%)	4 (11%)
Decreased appetite	0	0	0	1 (33%)	0	1 (25%)	1 (20%)	0	0	0	1 (13%)	0	0	4 (11%)
					Gra	ade 3 TRA	Es (ALL)							
Fatigue	0	0	0	0	0	0	0	0	0	0	0	3 (27%)	2 (100%)	4 (11%)
Anemia	0	0	0	0	0	0	0	0	0	0	1 (13%)	0	0	1 (3%)
Neutropenia	0	0	0	0	0	0	0	0	1 (11%)	0	0	0	0	1 (3%)
Vomiting	0	0	0	0	0	0	0	0	0	0	0	0	1 (50%)	1 (3%)

NUCANA

• No Grade 4 or 5 TRAEs

MTD: 1,350 mg/m²


MTD: maximum tolerated dose

* number of patients receiving each dose level at any time during the study

** total number of patients who experienced TRAE



Duration of Treatment




c.melanoma, cutaneous melanoma; GE, gastro/esophageal; m. melanoma, mucosal melanoma; o.melanoma, ocular melanoma; p. meso, pleural mesothelioma

NUTIDE 701

NUCANA

Clinical Activity in Cutaneous Melanoma



All melanoma patients had prior immunotherapy

NUCANA

* New Lesion(s)

NUC-7738 treatment enabled complete resection (R0)



Encouraging Efficacy Signals

Metastatic Melanoma

62 years, female 2 prior lines

1) nivolumab + ipilimumab: discontinued within **1 month**

- 2) CK7 inhibitor: progressed at **1 month**
- NUC-7738 starting dose 14 mg/m² (8 dose escalations)
- 18 months treatment duration (Stable Disease 12 months)
- 14% reduction in tumor volume

Metastatic Melanoma

65 years, female **1 prior line**

1) nivolumab + ipilimumab: discontinued within **1 month**

- NUC-7738 starting dose 400 mg/m² (1 dose escalation)
- 11 months treatment duration (Stable Disease 9 months)
- NUC-7738 treatment enabled complete resection patient had diffuse disease that was inoperable prior to NUC-7738

Metastatic Clival Chordoma

72 years, female **1 prior line**

1) imatinib: progressed at **19 months**

- NUC-7738 dose 1,350 mg/m²
- Stable disease 6 months
- Bleeding from nasal lesion resolved
- 45% reduction in mandibular lesion
- Complete disappearance of lip lesion

Metastatic Lung Adenocarcinoma

65 years, male **2 prior lines**

1) carboplatin + pemetrexed: progressed at **6 months**

2) docetaxel: progressed at 4 months

- NUC-7738 starting dose 42 mg/m² (4 dose escalations)
- Treatment duration 6 months
- 46% reduction in lung lesion 1
- Change in character in lung lesion 2
 - small dense core surrounded by a larger diffuse "ground-glass" periphery

NUTIDE 701

NUCÁNA


Encouraging Efficacy Signals

Metastatic Lung Adenocarcinoma

65 years, male - 2 prior lines


Target Lesion 1:

Encouraging signs of anti-tumor activity with a **46% reduction** in lesion between week 8 - 16 (41mm to 22mm)



Positive change in character (week 8 - 16), with a smaller dense core surrounded by a larger diffuse "ground-glass" periphery

Target Lesion 2:



NUTIDE 701

Symeonides et al (2020) Ann Oncol: 31: S501 Abstract ID: 600TiP (ESMO September 2020): Data cut-off 14 August 2020

NUCÁNA

Worldwide exclusive rights for all programs: 844 granted patents and 263 pending applications*

Key Patents	Status	Expiration ⁺ (excluding any extensions)	Territories
NUC-3373	157 granted, 95 pending, including:		
Composition of matter	Granted (US, EP, JP)	2032	+ others
Formulation	Granted (JP), Pending (US, EP)	2036	+ others
Manufacturing process	Pending	2043	+ others
Use	Pending	2037 / 2038	+ others
NUC-7738	77 granted, 36 pending, including:		
Composition of matter	Granted (US, EP, JP)	2035	+ others
Formulation	Pending	2036	+ others
Manufacturing process	Pending	2038	+ others
Use	Pending	2038	+ others
-ACELARIN	493 granted, 94 pending, including:		
Composition of matter	Granted (US, EP), Pending (JP)	2033 / 2035	+ others
Formulation	Granted (US, EP, JP)	2035	+ others
Manufacturing process	Granted (US, EP, JP)	2035 / 2036	+ others
Use	Granted (US, EP, JP)	2035 / 2038	+ others

*As of March 29, 2023 *Expiration for pending patents if granted

NUC-3373	PHASE	INDICATION	COMBINATION	MILESTONE	
NUTIDE 302 Study	Phase 2	Colorectal Cancer	irinotecan bevacizumab	NUFIRI + bev data	
	rilase 2		oxaliplatin bevacizumab	NUFOX + bev data	
NUTIDE 323 Study	NUTIDE 323 Study Phase 2 randomized		irinotecan bevacizumab	Randomized data NUFIRI + bev vs. FOLFIRI + bev	
NUTIDE 303 Study	Phase 1b	Solid Tumors	pembrolizumab	NUC-3373 + pembrolizumab data	
	Phase to	Lung Cancer	docetaxel	NUC-3373 + docetaxel data	

NUC-7738					
NUTIDE 701 Study	Phase 2	Solid Tumors	monotherapy	NUC-7738 data	
	Plidse 2	Solid Tumors	pembrolizumab	NUC-7738 + pembrolizumab data	

Improving Survival Outcomes •

Harnessing phosphoramidate chemistry to establish a new era in oncology

Strong IP Protection

Worldwide exclusive rights

Significant Milestones •

Numerous value inflection points throughout 2023

Strong Cash Position

Cash runway into 2025

Experienced Team

Nasdaq : NCNA

Accomplished management team Backed by leading biotech investors

NUC-3373: Seeking to Replace 5-FU

Targeted & more potent TS inhibitor Encouraging efficacy signals Favorable safety profile Improved dosing schedule

Addressing Blockbuster Market Opportunities

CRC is the 3rd most common cancer 5-FU is the global standard of care

NUC-7738: Novel Anti-Cancer Medicine

Differentiated mode of action Encouraging anti-cancer activity







E: info@nucana.com

Global Headquarters: 3 Lochside Way, Edinburgh, EH12 9DT United Kingdom